The psychedelic renaissance is gaining mainstream traction, with celebrities like Joe Rogan and political figures like President Trump pushing for accelerated access to these substances for clinical research and treatment. Yet beneath this wave of enthusiasm lies a troubling reality: the benefits of this revolution are not reaching everyone equally. Historically, communities of color have been disproportionately harmed by the war on drugs, and now they risk being excluded from the therapeutic potential of psychedelics. This Q&A explores the roots of this disparity, recent policy shifts, and what it means for equity in mental health care.
1. What recent political developments have boosted psychedelic research?
In a surprising alignment, President Trump signed an executive order aimed at speeding up access to psychedelics for clinical research and treatment. The order came with support from high-profile figures like podcast host Joe Rogan, a vocal advocate for psychedelics, and members of the MAHA (Make America Healthy Again) movement. This move marks a significant shift from decades of stigmatization, where psychedelics were dismissed as dangerous club drugs with no clinical value. The executive order directs federal agencies to remove barriers to studying substances like psilocybin, MDMA, and LSD, potentially leading to broader therapeutic use for conditions such as PTSD, depression, and addiction.
2. How have psychedelics been historically viewed in mainstream medicine?
For generations, psychedelics were marginalized in mainstream medicine. Despite evidence of their use dating back to Neanderthals and indigenous rituals, they were classified as Schedule I drugs in the 1970s, meaning they were deemed to have no accepted medical use and a high potential for abuse. This prohibition stifled research for decades, relegating psychedelics to the category of recreational club drugs associated with counterculture movements. Only recently have clinical trials resumed, revealing powerful therapeutic potential for mental health disorders. However, this revival has largely occurred in predominantly white, affluent settings, overlooking the historical and ongoing harm these same substances caused in communities of color through draconian drug laws.
3. Why are people of color being left behind in the psychedelic renaissance?
The psychedelic revolution is creating a two-tiered system: privileged, mostly white participants can access expensive retreats and clinical trials, while communities of color, who often bear the brunt of the war on drugs, remain excluded. Black and Latino individuals are underrepresented in psychedelic research, despite facing higher rates of trauma and mental health conditions. Furthermore, the legalization and decriminalization efforts often ignore the racial disparities in drug enforcement. For example, while psychedelics become available for therapeutic use in some states, people of color continue to be arrested at disproportionate rates for similar substances. This inequity stems from systemic racism, lack of diverse researchers, and the high cost of treatment. Without deliberate inclusion, the psychedelic revolution risks reinforcing existing health disparities.
4. What role did the war on drugs play in shaping current disparities?
The war on drugs, launched in the 1970s, had a devastating impact on communities of color. Psychedelics like LSD and psilocybin were heavily criminalized, leading to mass incarceration and long-term stigma. While white users were often portrayed as misguided youth, people of color faced harsher sentences and social ostracization. This legacy persists today: even as psychedelics are rebranded as therapeutic tools, the same substances that once ruined lives now offer hope—but only to those who can afford access. The criminal justice system still disproportionately targets Black and brown individuals for drug offenses, creating a paradox where the same plant medicines that heal one demographic incarcerate another.
5. How can we ensure equitable access to psychedelic therapy?
To avoid repeating historical injustices, advocates and policymakers must prioritize equity. This includes funding research in diverse communities, lowering the cost of treatments, and expunging past criminal records for psychedelic-related offenses. Inclusion of people of color as researchers, clinicians, and participants is essential. Additionally, legalization models should incorporate restorative justice practices, such as reinvesting tax revenue from psychedelic sales into communities harmed by the war on drugs. Public education campaigns must also debunk myths that psychedelics are only for the wealthy or counterculture. Without these steps, the psychedelic revolution will remain a privilege, not a right, for people of color.
6. What does the Trump executive order mean for underrepresented groups?
Trump's executive order, while a positive step for accelerating research, does not explicitly address racial equity. It focuses on removing bureaucratic obstacles for clinical trials but lacks provisions for diversifying study populations or ensuring affordability of future treatments. If left unchecked, this could widen the gap: well-funded institutions will rush to market expensive therapies, while low-income and minority communities remain underserved. However, the order does create an opportunity for advocates to push for inclusive guidelines. By leveraging the renewed federal interest, activists can demand that any expansion of psychedelic access includes mandatory diversity targets, community outreach, and protections against discrimination in treatment settings.